BioMarin Pharma (BMRN) Tops Q3 EPS by 13c, Revenue Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioMarin Announces Third Quarter 2016 Financial Results
October 27, 2016 4:03 PM EDT- Third Quarter 2016 Total BioMarin Revenues Increase 34% Year over Year to $280 million
- Vimizim Net Product Revenues Increase 25% Year over Year to $81 million in the Third Quarter 2016
- Kuvan Net Product Revenues Increase 42% Year over Year to $91 million in the Third Quarter 2016 Â
 Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)
  Three Months Ended September... More